Form D · Biotechnology

AI Proteins, Inc.

Boston, MA · CIK 0001903127

Offering snapshot reported Apr 4, 2024 · SEC filing

Reported sold
$5M
Offering amount: $10M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 21, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 4, 2024Initial$4,995,000No comparison8SEC filing
Aug 4, 2023Initial$8,300,000No comparison7SEC filing
Jan 21, 2022Initial$11,321,003No comparison38SEC filing

Offering details

Securities
Debt
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-509608

Source: Form D, filed Apr 4, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mark Alles Director
Chris Bahl Director, Executive
Arthur Becker Director
Noah Beerman Director, Executive
Namandje Bumpus Director
Marc A. Cohen Director, Executive
Drew Dennison Director
Wendy Dwyer Executive
Bruce Evans Director
Todd Kaloudis Director
Bill Mc Kee Director
Geoff Meyerson Director
Carl Novina Director
Julia A. Novina Executive
Elena Prokupets Director
Malcolm Salter Director
Bobby Sandage Director
Dominique Verhelle Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
20 Overland Street
Boston, MA, 02215